SNMMI Applauds FDA Approval of Flutemetamol F-18 Injection (Vizamyl)
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) applauds the U.S. Food and Drug Administration (FDA) for its approval of flutemetamol F-18 injection (Vizamyl) for positron emission tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. SNMMI is pleased that the FDA has again recognized the value of nuclear medicine and molecular imaging radiotracers as an adjunct tool for other diagnostic evaluations for patients with suspected Alzheimer's disease. We encourage the FDA to continue reviewing and, when appropriate, approving other nuclear medicine and molecular imaging radiopharmaceuticals that can play a role in improving patient care.
For more information visit interactive.snm.org